Cipla Ltd one of the world’s largest generic pharmaceutical companies with a presence in over 170 countries, has renewed contract of undisclosed value with VLife, in the area of genotoxicity predictions of compounds using VLife's proprietary technology platform.

VLife has been providing genotoxicity pediction services to several generic companies around the world. The renewal of contract with Cipla is a major step in establishing VLife's strengths in the area of genotoxicity prediction, analysis and justification.

About Cipla Ltd.:
Cipla Ltd is one of the world’s largest generic pharmaceutical companies with a presence in over 170 countries. They are committed for making affordable, world-class medicines that meet the needs of patients across therapies. They also offer services like consulting, commissioning, plant engineering, technical know-how transfer and support.

About VLife:
VLife Sciences Technologies, a divison of NovaLead Pharma Pvt. Ltd., Pune is a leading provider of licensed software and research solutions for research projects in a variety of sectors including genotoxicity predictions . The software offers numerous unique and specialized features for applications in computer aided molecular discovery, bioinformatics, biotechnology and chemoinformatics. Technologies developed by VLife are unique, novel and offer advantages in terms of speed and accuracy thus leading to improved outcome from research projects. VLife offers the VLifeMDS® suite for a comprehensive approach to computer aided drug design and the QSARpro® suite for advanced quantitative structure activity relationships analysis leading to new molecule design.
VLife's ViTAL® for predicting genotoxic potential of impurities and degradation products associated with drug substance or API.

For more details please visit: www.vlifesciences.com or contact us at info@vlifesciences.com